On April 12, 2018 Active Biotech (NASDAQ STOCKHOLM: ACTI) reported that its partner NeoTX Therapeutics Ltd. will present new data for ANYARA (Naptumumab Estafenatox) at the Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) in Chicago on April 14-18, 2018 (Press release, Active Biotech, APR 12, 2018, View Source [SID1234525482]). The poster Naptumumab Estafenatox Induces T cells Tumor Recognition, Turning anti-PD1 Unresponsive "Cold" Tumors into "Hot" Responsive Tumors will be presented between 1:00 p.m. and 5:00 p.m. local time on April 16, 2018, at the session "Immune Checkpoints 2". The data to be presented demonstrates a synergistic anti-tumor effect when ANYARA is combined with a PD-1 checkpoint inhibitor in several different tumor models that are marginally responsive to PD-1 inhibition.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Checkpoint inhibitors are drugs that unleash an immune system attack against tumor cells. It is well established that a key factor that limits the effectiveness of checkpoint inhibition is tumor recognition. ANYARA is a Tumor Targeted Superantigen (TTS) that enhances the ability of the immune system to recognize and kill the tumors and is therefore attractive for combination therapy to enhance the efficacy of checkpoint inhibition.

"We are enthusiastic that our partner NeoTX has been selected to present these important data showing that ANYARA, through its tumor-targeted mode of action, enhances the effect of PD-1 inhibition and thereby potentially increases the clinical benefit of such treatment in the long term," says Helén Tuvesson, CEO of Active Biotech.

A summary of the poster presentation will be published at: View Source!/4562/presentation/9330

About ANYARA

ANYARA is a Tumor Targeting Superantigen (TTS) that enhances the ability of the immune system to recognize and kill tumors. Active Biotech has an agreement with NeoTX Therapeutics Ltd since October 2016 for the global development and commercialization of ANYARA for the treatment of cancer. Clinically, the development of ANYARA has focused on cancer forms with a high medical need. Positive data was reported from clinical Phase 1 and 2/3 studies in lung cancer, renal cell cancer and pancreatic cancer, where ANYARA was studied both as a single agent and in combination with an established tumor therapy in patients with advanced cancer. Preparations for a clinical trial in combination with a checkpoint inhibitor are ongoing.

Lund, April 12, 2018
Active Biotech AB (publ)

For further information, please contact:
Helén Tuvesson, CEO
Tel. +46 46 19 20 95
Email: [email protected]

Hans Kolam, CFO
Tel. +46 46 19 20 44
Email: [email protected]

On April 12, 2018 Athersys, Inc. (Nasdaq:ATHX) reported that it will release its first quarter 2018 financial results at approximately 4:00 PM Eastern Time on Thursday, May 10, 2018, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results (Press release, Athersys, APR 12, 2018, View Source [SID1234525286]). Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will host the call as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date May 10, 2018
Time 4:30 p.m. (Eastern Time)
Telephone access: US and Canada (800) 273-1254
Telephone access: International (973) 638-3440
Access code 1189915
Live webcast www.athersys.com under Investors section

A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM Eastern Time on May 24, 2018 at the aforementioned URL, or by dialing (800) 585-8367 or (855) 859-2056 in the U.S. and Canada, or from abroad (404) 537-3406, and entering access code 1189915.

On April 11, 2018 Lytix Biopharma Reported that it will present data at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place from 14th – 18th April 2018 at McCormick Place North/South, Chicago, Illinois, US (Press release, Lytix Biopharma, APR 11, 2018, View Source
[SID1234525270]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr Mikael J. Pittet, Associate Professor at Harvard Medical School, Senior Faculty of the Center for Systems Biology (CSB) at Massachusetts General Hospital (MGH) and Director of the CSB Cancer Immunology Program will present the data in a poster presentation from 8-12 am on Wednesday April 18. Previous experimental studies identified LTX-315’s ability to control cancer in mice grafted with various tumor cell lines triggering tumor-specific T cells. The analyses has now been extended to conditional genetic mouse models of both melanoma (driven by Braf and Pten alterations) and soft tissue sarcoma (driven by Kras and P53 alterations). In these genetic models, cancer cells are derived from somatic cells that are transformed in their normal tissue microenvironment and progress to high-grade tumors that are poorly infiltrated by T cells and typically resist prescribed chemo- and immunotherapeutic treatments.

"We are excited to present this data at AACR (Free AACR Whitepaper) in conjunction with Dr Pittet’s team which shows that LTX-315 not only delays tumor progression substantially in both models, but also profoundly alters the tumor microenvironment, most notably characterized with CD8+ T cell, NK cell and dendritic cell infiltration. A similar transition from a ‘cold’ to a ‘hot’ tumor microenvironment is seen in patients with melanoma, sarcoma and breast cancer after treatment with LTX-315. Furthermore, CD8+ T cell depletion in mice abrogated long-term antitumor efficacy of LTX-315, indicating that these cells are required for drug-induced tumor control. Importantly, the ability to convert non-T-cell-infiltrated tumors into ones that display antitumor T cell immunity opens the possibility to prime and make unresponsive tumors sensitive for systemic immune treatments," commented Dr Edwin Klumper, CEO of Lytix Biopharma.

View Source!/4562/presentation/8122

April 18, 2018, 8:00 AM – 12:00 PM
Section 25 Session PO.CL06.08 – Immunomodulatory Agents and Interventions 3

5549 / 5 – Antitumor efficacy of the oncolytic peptide LTX-315 in genetic mouse models that resist conventional chemo- and immunotherapeutic treatments

M. J. Pittet1, H-W. Liao1, B. Sveinbjørnsson2, Ø. Rekdal2; 1Massachusetts Gen. Hosp., Boston, MA, 2Lytix Biopharma, Tromso, Norway

On April 11, 2018 ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, reported its presence at the Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) taking place April 14-18, 2018 in Chicago, USA (Press release, ADC Therapeutics, APR 11, 2018, View Source [SID1234525271]). Two poster presentations will highlight strong preclinical data for its two new investigational programs ADCT-601 targeting AXL and ADCT-701 targeting DLK-1. In addition, Dr. Jaewoong Lee, of The Beckman Institute of the City of Hope will make an oral presentation on novel preclinical data for ADCT-301 targeting CD25.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our two new investigational programs show compelling efficacy and safety in preclinical studies," said Dr. Jay Feingold, Chief Medical Officer and Senior Vice President of Clinical Development at ADCT. "These results provide an important step to advance ADCT-601 and ADCT-701 into the clinic and enlarge our pipeline of PBD-based ADCs in multiple ongoing clinical trials for the treatment of both solid and hematological cancers."

Poster titles and highlights of the data that will be presented are available on the AACR (Free AACR Whitepaper) conference website at www.aacr.org and include the following:

ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors Abstract #744, April 15, 1:00 pm – 5:00 pm CT

– ADCT-701 is an ADC composed of a humanized IgG1 antibody against human DLK1, site-specifically conjugated using GlycoConnectTM technology to PL1601, which contains a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199.

– ADCT-701 demonstrated potent and specific in vitro and in vivo anti-tumor activity in DLK1-expressing cancer-derived models and it was stable and well tolerated in rats.

Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors Abstract #2792A, April 16, 1:00 pm – 5:00 pm CT

– ADCT-601 is an ADC composed of a humanized IgG1 antibody against human AXL, site-specifically conjugated using GlycoConnectTM technology to PL1601, which contains a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199.

– ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in various cancer-derived models with different levels of membranous AXL, and it was stable and well tolerated in rats.

CD25 enables oncogenic BCR- and TCR-signaling and represents a therapeutic target in lymphoblastic malignancies Abstract #2983, April 16, 2018, 4:05 PM – 4:20 PM

– Novel data identifies CD25 as a previously unrecognized feedback regulator of oncogenic B/TCR-signaling supporting CD25 as a therapeutic target in refractory lymphoid malignancies.

– ADCT-301 demonstrated durable remissions in patient-derived Ph+ ALL cells PDX models

On April 11, 2018 Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins as a new class of potent and selective cancer medicines, reported that the company will present preclinical data related to PEN-866 at the 2018 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, occurring April 14-18, 2018 in Chicago, IL (Press release, Tarveda Therapeutics,APR 11, 2018, View Source [SID1234525272]). PEN-866 is a miniature drug conjugate designed to treat patients with solid tumor types known to be sensitive to topoisomerase 1 inhibitors such as SN-38, the payload of PEN-866. The presentation will address the combination of PEN-866 with PARP inhibitors in models of ovarian cancer, lung cancer and colorectal cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentation are as follows:

Title: Combination of the miniature drug conjugate PEN-866 with PARP inhibitors as a rational approach to overcoming limitations of PARP inhibitor monotherapy
Date:

April 18, 2018
Time:

8:00 AM – 12:00 PM CT
Location:

Section 37, McCormick Place North/South, Chicago, IL

About PEN-866
PEN-866 exploits the activation of Heat Shock Protein 90 (HSP90) in tumors to accumulate and release its potent anti-cancer payload, SN-38. PEN-866 is a miniature conjugate that comprises a small molecule, HSP90-targeting ligand linked to SN-38, the active metabolite of irinotecan. The conjugate accumulates and is retained in tumors, and by way of a sustained release of SN-38, causes prolonged DNA damage and tumor regressions in multiple patient-derived and other xenograft tumor models.

About Pentarins
Tarveda is developing Pentarins, potent and selective miniature drug conjugates with high affinity for specific cell surface and intracellular targets. Pentarins are engineered to bind to their tumor cell targets and provide sustained release of their potent therapeutic payloads deep into solid tumor tissue. Comprised of a targeting ligand conjugated to a potent cancer cell killing agent through a tuned chemical linker, Pentarins are designed to overcome the deficits of both larger antibody drug conjugates and small molecules that limit their therapeutic effectiveness against solid tumors. Together, the components of Tarveda’s Pentarins have distinct, yet synergistic, anticancer attributes: the small size of Pentarins allows for rapid and deep penetration into the tumor tissue, the ligand’s targeting ability allows for specific binding and retention in tumor cells, and the chemical linker is tuned to optimize the release of the potent, cell killing payload inside the cancer cells for efficacy.